Whether rubicatin/rubitin is an injection form and instructions for use

Lurbinectedin is a new anti-tumor drug that has been approved in many countries for the treatment of small cell lung cancer (SCLC) and other advanced solid tumors. This drug is an intravenous injection preparation and is not suitable for oral or subcutaneous injection. Its dosage form is designed to maintain the peak blood concentration in a short period of time and enhance DNA damage to tumor cells, thereby achieving a stronger inhibitory effect on proliferation. According to the recommendations of overseas clinical guidelines, the standard dosage regimen is intravenous infusion once every 21 days, and each dose is calculated based on the body surface area, which is 3.2 mg/m². The drug is usually dissolved in a certain volume of physiological saline and is slowly infused intravenously over about 60 minutes. It must be used in a hospital or medical institution with experience in tumor treatment to ensure safe monitoring.

The administration method of rubitin is relatively standardized. Before infusion, patients need to undergo blood routine and liver and kidney function tests to ensure that the indicators are within the acceptable range to avoid serious toxic reactions during the infusion. On the day of administration, doctors often dynamically adjust the dose based on changes in the patient's weight and the occurrence of side effects. Some patients may need to reduce the dose to 2 mg/m². Since it is a cytotoxic drug, it is necessary to closely observe whether common reactions such as bone marrow suppression, nausea and vomiting, fatigue, etc. occur after infusion. If necessary, it can be used in combination with antiemetics and supportive care drugs.

As an injection dosage form, the design of rubitidine fully reflects the sensitivity of the drug to time control, which also determines that it requires professional operation during the treatment process and is not suitable for self-management by patients. At present, the injection form of this drug has been commercialized in European and American countries and Hong Kong, China, providing a new drug option for the treatment of advanced tumors. Combined with its mechanism and usage specifications, rubitidine, as an intravenous drug, not only emphasizes dosage accuracy, but also puts forward higher requirements for the treatment environment and pre-medication assessment. It is an injectable anti-cancer drug that needs to be used under the management of a professional cancer center.

Reference materials:https://www.zepzelca.com/